2020 Insomnia (Sleep Deprivation) Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs

2020 Insomnia (Sleep Deprivation) Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs

  • February 2020 •
  • 107 pages •
  • Report ID: 5863912 •
  • Format: PDF
The 2020 Insomnia (Sleep Deprivation) pipeline report presents a comprehensive overview of the research and development of Insomnia (Sleep Deprivation) drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Three drugs in Research phase, Six drugs in pre-clinical phase, One drug in Phase 1, 11 drugs in Phase 2, and four drugs in Phase 3

As of February 2020, the Insomnia (Sleep Deprivation) pipeline remains robust with 26 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Insomnia (Sleep Deprivation) treatment. Diverse types of targeted therapies are being explored through clinical trials including Beta 1 adrenergic receptor antagonists; cannabinoid receptors; Casein kinase Idelta inhibitors; Casein kinase Iepsilon inhibitors; CYP1A2 activators; GABA A receptor agonists; GABA A receptor modulators; GABA B receptors; Histamine H1 receptor antagonists; Melatonin receptor agonists; Orexin receptor type 1 antagonists; Orexin receptor type 2 antagonists; Serotonin 1A receptor agonists; Serotonin 1D receptor agonists; Serotonin 2A receptor antagonists; Serotonin 2B receptor antagonists.

The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Insomnia (Sleep Deprivation) drug development history, latest news, and other developments.

It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.

Publisher Expertise
Our online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.

Scope:
• The report scope comprises of both pre-clinical phase and clinical phase development drugs for Insomnia (Sleep Deprivation) development
• Insomnia (Sleep Deprivation) pipeline compounds and molecules under study by both large scale and small companies are included in the report
• Insomnia (Sleep Deprivation) pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
• Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
• Further, orphan drug status, fast track designation, different grants awarded and special status for Insomnia (Sleep Deprivation) pipeline candidates included
• Business overview and snapshot of all companies involved in Insomnia (Sleep Deprivation) pipeline are included
• Latest market and pipeline developments are provided in the report

Insomnia (Sleep Deprivation) pipeline companies included in the report are- Amherst Pharmaceuticals LLC, Biohemp International Inc, Cennerv Pharma (S) Pte Ltd, Cosmas Therapeutics Development Inc, Druggability Technologies Holdings Ltd, Eisai Co Ltd, EUSOL Biotech Co Ltd, Evotec AG, Grupo Ferrer Internacional SA, Idorsia Pharmaceutical Ltd, Imbrium Therapeutics, Intra-Cellular Therapies Inc, Jazz Pharmaceuticals Plc, Johnson & Johnson, Linnet BioPharmaceuticals Inc, Minerva Neurosciences Inc, NB Health Laboratory Co Ltd, Neurim Pharmaceuticals Ltd, NeuroFix Therapeutics LLC, Overseas Pharmaceuticals Ltd, Sage Therapeutics Inc, Shionogi & Co Ltd, Taisho Pharmaceutical Holdings Co Ltd, Tritech Biopharmaceuticals Co Ltd, Zelda Therapeutics Pty Ltd

Insomnia (Sleep Deprivation) pipeline drugs profiled in the report include- Zolpidem oral spray, nebivolol, CB2810, UCM-765, DRGT-73, lemborexant, SM-1 (Diphenhydramine+lorazepam+zolpidem), EVT201, lorediplon, nemorexant, IMB-115, lumateperone, JNJ-48816274, seltorexant (JNJ-42847922), CYP1A2 Inducer for Insomnia, P005, piromelatine (Neu-P11), NFX91, CY18, CY20, SAGE-217, S-117957, TS-142, Zolpidem topical gel, cannabinoid receptors for Insomnia, sodium oxybate